Related Experiment Video
Updated: May 31, 2026

Optimization of Transesophageal Atrial Pacing to Assess Atrial Fibrillation Susceptibility in Mice
Published on: June 29, 2022
Monomorphic ventricular tachycardia caused by arsenic trioxide therapy for acute promyelocytic leukaemia
R A Ducas1, M D Seftel, J Ducas
1Section of Cardiology, Cardiac Sciences Department, St Boniface General Hospital, 401 Tache Avenue, Winnipeg, Manitoba, Canada.
Abstract:
Arsenic trioxide has become the treatment of choice for patients with acute promyelocytic leukaemia. Cardiovascular toxicity is known to occur with this therapy, in particular heart rhythm disorders due to QT interval prolongation. We present a case of ventricular arrhythmia with no QT prolongation in a patient receiving arsenic trioxide therapy.
More Related Videos
06:57Ablation of Ischemic Ventricular Tachycardia Using a Multipolar Catheter and 3-dimensional Mapping System for High-density Electro-anatomical Reconstruction
Published on: January 31, 2019
05:15Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk
Published on: July 27, 2022
Related Concept Videos
Dysrhythmias III: Characteristics of Dysrhythmias
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Dysrhythmias II: Classification of Tachyarrhythmias
Disturbances in Heart Rhythm
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
Dysrhythmias IV: Characteristics of Bradyarrhythmias
Mechanism of Cardiac Arrhythmias